NEWS

Press Releases

Media Coverage

Additional Partnerships

For all media inquiries, please contact media@tempus.com

02/25/2021
Tempus Announces Sequencing and Computational Biology Collaboration with Kronos Bio to Support the Development of CDK9 Inhibitor KB-0742

Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequenc...
02/23/2021
- Genomic Sequencing
Tempus and Precision Health Informatics Announce Precision Medicine Collaboration

Tempus, a leader in precision medicine and artificial intelligence, today announced its collaboration with Precision Health Informatics, a wholly-owned subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine in oncology. This collaboration aims to further precision medicine research through unique insights derived from Pre...
01/13/2021
- Genomic Sequencing
- Solid Tumor
Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the...
12/10/2020
- Genomic Sequencing
Bayer and Tempus Initiate Collaboration to Advance Patient Access to Genomic Testing and Precision Medicine

Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Te...
11/24/2020
Tempus CE Marks Its Broad-Panel Genomic Sequencing Test, xT

Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked its signature broad-panel genomic sequencing assay, xT. The CE marked xT test is now available for clinical use in Europe. As part of Tempus’ broader regulatory strategy, European clinicians and their patients...
06/22/2020
- Genomic Sequencing
- Neuro/Psych
Tempus Announces Christopher Mason, PhD, Joins as Vice President of Emerging Genome Technology

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Christopher Mason, PhD, has joined as the Vice President of Emerging Genome Technology. Dr. Mason has been a pioneer in next-generation sequencing (NGS) diagnostics, multi-omic approaches to modeling disease,...
06/01/2020
- Clinical Trials
- Genomic Sequencing
Tempus Launches Prospective “Priority” Research Study and Increases Support for Oncology Research Initiatives Despite Pandemic Challenges

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its study, along with a collaborative research initiative to expedite project needs during the COVID-19 pandemic. Many oncology research projects have been delayed as building the necessary datasets are difficult...
05/31/2020
Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Tempus|HRD, a test that identifies a...
05/29/2020
- Clinical Trials
- Genomic Sequencing
Tempus TIME Trial™ Program Reaches Critical Scale and Operational Milestones

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials....
02/03/2020
- Clinical Trials
- Genomic Sequencing
New Genomics Technology Puts Precision Oncology into Practice at Rush

Rush University Medical Center is the first health care organization to launch medical record company Epic’s module for genomic results, giving providers the tools they need to tailor patient care at the molecular level. Rush will use the module as part of its Precision Oncology Center to...

2 3 4